Cargando…

Prevalence of Quinolone Resistance of Extended-Spectrum β-Lactamase-Producing Escherichia coli with ST131-fimH30 in a City Hospital in Hyogo, Japan

Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolates are known to tolerate superior quinolone antimicrobials compared with other antibacterial agents. Among the clones belonging to sequence type (ST) 131 by multilocus sequence typing, the involvement of the H30-Rx subclone has be...

Descripción completa

Detalles Bibliográficos
Autores principales: Teramae, Masazumi, Osawa, Kayo, Shigemura, Katsumi, Kitagawa, Koichi, Shirakawa, Toshiro, Fujisawa, Masato, Miyara, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829264/
https://www.ncbi.nlm.nih.gov/pubmed/31635210
http://dx.doi.org/10.3390/ijms20205162
_version_ 1783465514069131264
author Teramae, Masazumi
Osawa, Kayo
Shigemura, Katsumi
Kitagawa, Koichi
Shirakawa, Toshiro
Fujisawa, Masato
Miyara, Takayuki
author_facet Teramae, Masazumi
Osawa, Kayo
Shigemura, Katsumi
Kitagawa, Koichi
Shirakawa, Toshiro
Fujisawa, Masato
Miyara, Takayuki
author_sort Teramae, Masazumi
collection PubMed
description Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolates are known to tolerate superior quinolone antimicrobials compared with other antibacterial agents. Among the clones belonging to sequence type (ST) 131 by multilocus sequence typing, the involvement of the H30-Rx subclone has been reported worldwide with various fimH genes encoding type 1 pili. We investigated 83 isolates of ESBL-producing E. coli and performed antimicrobial susceptibility test, CH (fumC/fimH) ST131 by typing the specific PCR. Moreover, mutation analysis of genes involved in quinolone antibiotic resistance (gyrA and parC) and ESBL genotypes were determined. As a result, 54 of 83 isolates (65.1%) of CH40-30 clones corresponding to ST131-fimH30 were detected, and all were resistant to levofloxacin. Mutations associated with this resistance were common, and included S83L and D87N of gyrA and S80I and E84V of parC. Subclone analysis revealed a high proportion of fimH30-non-Rx (40 isolates, 74.1%). Each subclone was characterized by ESBL genotype, and the CTX-M-15 type was mainly seen for fimH30-Rx, with the CTX-M-14 type or CTX-M-27 type seen for fimH30-non-Rx. This study suggests that an increase in ESBL-producing quinolone-resistant E. coli in a city hospital in Hyogo, Japan, was caused by the spread of subclones belonging to fimH30-non-Rx of ST131.
format Online
Article
Text
id pubmed-6829264
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68292642019-11-18 Prevalence of Quinolone Resistance of Extended-Spectrum β-Lactamase-Producing Escherichia coli with ST131-fimH30 in a City Hospital in Hyogo, Japan Teramae, Masazumi Osawa, Kayo Shigemura, Katsumi Kitagawa, Koichi Shirakawa, Toshiro Fujisawa, Masato Miyara, Takayuki Int J Mol Sci Communication Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolates are known to tolerate superior quinolone antimicrobials compared with other antibacterial agents. Among the clones belonging to sequence type (ST) 131 by multilocus sequence typing, the involvement of the H30-Rx subclone has been reported worldwide with various fimH genes encoding type 1 pili. We investigated 83 isolates of ESBL-producing E. coli and performed antimicrobial susceptibility test, CH (fumC/fimH) ST131 by typing the specific PCR. Moreover, mutation analysis of genes involved in quinolone antibiotic resistance (gyrA and parC) and ESBL genotypes were determined. As a result, 54 of 83 isolates (65.1%) of CH40-30 clones corresponding to ST131-fimH30 were detected, and all were resistant to levofloxacin. Mutations associated with this resistance were common, and included S83L and D87N of gyrA and S80I and E84V of parC. Subclone analysis revealed a high proportion of fimH30-non-Rx (40 isolates, 74.1%). Each subclone was characterized by ESBL genotype, and the CTX-M-15 type was mainly seen for fimH30-Rx, with the CTX-M-14 type or CTX-M-27 type seen for fimH30-non-Rx. This study suggests that an increase in ESBL-producing quinolone-resistant E. coli in a city hospital in Hyogo, Japan, was caused by the spread of subclones belonging to fimH30-non-Rx of ST131. MDPI 2019-10-18 /pmc/articles/PMC6829264/ /pubmed/31635210 http://dx.doi.org/10.3390/ijms20205162 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Teramae, Masazumi
Osawa, Kayo
Shigemura, Katsumi
Kitagawa, Koichi
Shirakawa, Toshiro
Fujisawa, Masato
Miyara, Takayuki
Prevalence of Quinolone Resistance of Extended-Spectrum β-Lactamase-Producing Escherichia coli with ST131-fimH30 in a City Hospital in Hyogo, Japan
title Prevalence of Quinolone Resistance of Extended-Spectrum β-Lactamase-Producing Escherichia coli with ST131-fimH30 in a City Hospital in Hyogo, Japan
title_full Prevalence of Quinolone Resistance of Extended-Spectrum β-Lactamase-Producing Escherichia coli with ST131-fimH30 in a City Hospital in Hyogo, Japan
title_fullStr Prevalence of Quinolone Resistance of Extended-Spectrum β-Lactamase-Producing Escherichia coli with ST131-fimH30 in a City Hospital in Hyogo, Japan
title_full_unstemmed Prevalence of Quinolone Resistance of Extended-Spectrum β-Lactamase-Producing Escherichia coli with ST131-fimH30 in a City Hospital in Hyogo, Japan
title_short Prevalence of Quinolone Resistance of Extended-Spectrum β-Lactamase-Producing Escherichia coli with ST131-fimH30 in a City Hospital in Hyogo, Japan
title_sort prevalence of quinolone resistance of extended-spectrum β-lactamase-producing escherichia coli with st131-fimh30 in a city hospital in hyogo, japan
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829264/
https://www.ncbi.nlm.nih.gov/pubmed/31635210
http://dx.doi.org/10.3390/ijms20205162
work_keys_str_mv AT teramaemasazumi prevalenceofquinoloneresistanceofextendedspectrumblactamaseproducingescherichiacoliwithst131fimh30inacityhospitalinhyogojapan
AT osawakayo prevalenceofquinoloneresistanceofextendedspectrumblactamaseproducingescherichiacoliwithst131fimh30inacityhospitalinhyogojapan
AT shigemurakatsumi prevalenceofquinoloneresistanceofextendedspectrumblactamaseproducingescherichiacoliwithst131fimh30inacityhospitalinhyogojapan
AT kitagawakoichi prevalenceofquinoloneresistanceofextendedspectrumblactamaseproducingescherichiacoliwithst131fimh30inacityhospitalinhyogojapan
AT shirakawatoshiro prevalenceofquinoloneresistanceofextendedspectrumblactamaseproducingescherichiacoliwithst131fimh30inacityhospitalinhyogojapan
AT fujisawamasato prevalenceofquinoloneresistanceofextendedspectrumblactamaseproducingescherichiacoliwithst131fimh30inacityhospitalinhyogojapan
AT miyaratakayuki prevalenceofquinoloneresistanceofextendedspectrumblactamaseproducingescherichiacoliwithst131fimh30inacityhospitalinhyogojapan